Topical Rapamycin Effective for TSC-Related Facial Angiofibromas
HealthDay News — Topical rapamycin seems effective for tuberous sclerosis complex (TSC)-related facial angiofibromas, according to a study published online May 23 in JAMA Dermatology.
Mary Kay Koenig, MD, from The University of Texas Health Science Center at Houston, and colleagues examined the efficacy and safety of topical rapamycin for TSC-related facial angiofibromas in a study involving 179 patients. Participants were randomized in a 1:1:1 ratio to topical formulation containing 1% rapamycin, 0.1% rapamycin, or vehicle alone (59, 63, and 57 patients, respectively). The formulation was applied daily to designated areas at bedtime.
The researchers observed clinically meaningful and statistically significant improvement in facial angiofibromas for 1 and 0.1% rapamycin versus vehicle only, and for 1 vs 0.1% rapamycin; most of the improvement was seen in the first month. The Angiofibroma Grading Scale mean improvement at six months was 16.7, 11.0, and 2.1 points for 1 and 0.1% rapamycin and vehicle only, respectively (P<.001 for 1 and 0.1% vs vehicle only). End-of-treatment photos were rated better than baseline for 81.8, 65.5, and 25.5% of patients in the 1 and 0.1% rapamycin groups and the vehicle group, respectively (P<.001 for all three pairwise comparisons).
"Topical rapamycin appears effective and safe for treatment of TSC-related facial angiofibromas," the authors write. "In this trial, the preferred dose was 1 percent once daily."
Several authors disclosed financial ties to Novartis; one author disclosed ties to MedStudy. Several authors have a provisional patent pending.